RET is an inclusion criterion in 21 clinical trials for non-small cell lung carcinoma, of which 14 are open and 7 are closed. Of the trials that contain RET status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 13 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].

Cabozantinib, pembrolizumab, pralsetinib, selpercatinib, and vandetanib have evidence of efficacy in patients with RET mutation in non-small cell lung carcinoma [4].

RET is an inclusion criterion in 7 clinical trials for thyroid gland medullary carcinoma, of which 6 are open and 1 is closed. Of the trials that contain RET status and thyroid gland medullary carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

Pralsetinib, selpercatinib, and vandetanib have evidence of efficacy in patients with RET mutation in thyroid gland medullary carcinoma [4].

RET is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RET status and thyroid gland carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

Pralsetinib and selpercatinib have evidence of efficacy in patients with RET mutation in thyroid gland carcinoma [4].

RET is an inclusion criterion in 20 clinical trials for malignant solid tumor, of which 20 are open and 0 are closed. Of the trials that contain RET status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open), 7 are phase 1/phase 2 (7 open), 9 are phase 2 (9 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [4].

RET is an inclusion criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain RET status and melanoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

RET is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and colorectal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 2 are phase 3 (2 open) [4].

RET is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

RET is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain RET status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [4].

RET is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

RET is an inclusion criterion in 2 clinical trials for lymphoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain RET status and multiple myeloma as inclusion criteria, 2 are phase 2 (2 open) [4].

RET is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

RET is an inclusion criterion in 2 clinical trials for thyroid gland papillary carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RET status and thyroid gland papillary carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

RET is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for adrenal cortex carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and adrenal cortex carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for adrenal gland pheochromocytoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and adrenal gland pheochromocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for alveolar soft part sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and alveolar soft part sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains RET status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for clear cell sarcoma of soft tissue, of which 1 is open and 0 are closed. Of the trial that contains RET status and clear cell sarcoma of soft tissue as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and Ewing sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains RET status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and hepatoblastoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains RET status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and lung adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RET status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and neuroendocrine carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and rhabdomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RET is an inclusion criterion in 1 clinical trial for Wilms tumor, of which 1 is open and 0 are closed. Of the trial that contains RET status and Wilms tumor as inclusion criteria, 1 is phase 2 (1 open) [4].